Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
Year: 2026
Type: article
Study design: Clinical Trial
Source: New England Journal of Medicine
Authors: Brian M. Wolpin, Wungki Park, Ignacio Garrido-Laguna, Alexander Spira, Alexander Starodub, David Sommerhalder, Salman R. Punekar, Minal Barve, Meredith Pelster, Benjamin Herzberg, Nilofer S. Azad, Joel Randolph Hecht, Sai Hong Ignatius Ou, Tong Lin, Sumit Kar, Lin Tao, Rashmi Vora, Aparna Hegde, Kyaw Aung, David S. Hong
Institutions: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Huntsman Cancer Institute, Christ Hospital, NYU Langone Health, Mary Crowley Cancer Research Center, Columbia University, Sidney Kimmel Comprehensive Cancer Center, University of California, Los Angeles, University of California, Irvine, Revolution Medicines (United States), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Revolution Medicines
OpenAlex ID: W7160408317